3月31日 - ** 生物技术公司Elicio Therapeutics的ELTX.O股价下跌14%，跌至6.71美元的两个多月低点。
** ELTX现在预计其主要实验性疫苗ELI-002的中期研究数据将于2025年第三季度 (link)，而之前的预期是2025年上半年 (link)
** 该公司正在测试针对某些类型实体瘤的疫苗，这些瘤是由KRAS基因突变引起的，常见于胰腺癌、结直肠癌和非小细胞肺癌。
** 2024 年，ELTX 的净亏损也将比 2023 年扩大 (link)
** 截至上次收盘，ELTX 在过去 12 个月中上涨了 2.5
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.